Novo Nordisk experimental drug CagriSema shows 25% weight loss in women

Novo Nordisk has reported that its experimental obesity medication, CagriSema, is associated with an average body weight reduction of 25% in women with obesity or overweight. These findings come from a post-trial analysis of the Phase 3 REDEFINE 1 clinical trial, which included approximately 2,300 women over a 68-week period.

In the analysis, participants receiving a combination of 2.4 mg of cagrilintide and semaglutide saw an estimated 25% weight loss, compared to 3% in the placebo group. The broader trial, which involved over 3,400 adults, showed an average weight loss of 22.7% for those using CagriSema.

A secondary evaluation categorized roughly 1,900 women by reproductive stage. Results indicated an estimated weight loss of 26.7% for premenopausal women, 24.8% for perimenopausal women, and 23.1% for postmenopausal women. Researchers noted that while these differences were observed, further study is required to determine if menopause stage significantly dictates treatment response.

CagriSema combines semaglutide—the active ingredient in Wegovy and Ozempic—with cagrilintide to target hunger and fullness pathways. The drug also showed links to reduced waist circumference across all studied groups.